Get started
Work

LBA71 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743

Year: 2022
Type: conference-abstract
DOI: 10.1016/j.annonc.2022.08.077
Authors: G. Zalcman, Y. Oulkhouir, R. Cornelissen, L. Greillier, J.R. Rodriguez Cid, J. Mazieres, P. Briggs, A.K. Nowak, A. Tsao, N. Fujimoto, S. Peters, A.S. Mansfield, S. Popat, A. Nassar, J. Bushong, N. Hu, T. Spires, D. Balli, L. Eccles, P. Baas
Institutions: Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Bichat-Claude-Bernard, Centre Hospitalier Universitaire de Caen Normandie, Erasmus MC Cancer Institute, Centre National de la Recherche Scientifique, Inserm, Aix-Marseille Université, Hôpital Nord, Centre de Recherche en Cancérologie de Marseille, Instituto Nacional de Enfermedades Respiratorias, Université Toulouse III - Paul Sabatier, Centre Hospitalier Universitaire de Toulouse, Hôpital Larrey, Monash Medical Centre, The University of Western Australia, Sir Charles Gairdner Hospital, The University of Texas MD Anderson Cancer Center, Okayama Rosai Hospital, Centre Hospitalier Universitaire Vaudois, Mayo Clinic, Royal Marsden Hospital, Bristol-Myers Squibb (United States), Leiden University Medical Center, The Netherlands Cancer Institute
Language: English
Field: Medicine
Open Access status: bronze
Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, PharmaMar, Ono Pharmaceutical
OpenAlex ID: W4297982041
Cites:
Cited by: 6
Related to: 10